ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Omeros Corporation

Omeros Corporation (OMER)

10.00
-0.11
(-1.09%)
Cerrado 24 Diciembre 3:00PM
10.00
0.00
( 0.00% )
Pre Mercado: 3:10AM

Su centro para precios en tiempo real, ideas y debates en vivo

Estadísticas y detalles clave

Último Precio
10.00
Postura de Compra
9.35
Postura de Venta
13.00
Volume Operado de la Acción
-
0.00 Rango del Día 0.00
2.76 Rango de 52 semanas 13.60
Capitalización de Mercado [m]
Precio Anterior
10.00
Precio de Apertura
-
Hora
Última hora de negociación
-
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
957,359
Acciones en circulación
57,949,760
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-4.92
Beneficio por acción (BPA)
-2.03
turnover
-
Beneficio neto
-117.81M

Acerca de Omeros Corporation

Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injec... Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
Sede
Tumwater, Washington, USA
Fundado
-
Omeros Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker OMER. The last closing price for Omeros was US$10. Over the last year, Omeros shares have traded in a share price range of US$ 2.76 to US$ 13.60.

Omeros currently has 57,949,760 shares in issue. The market capitalisation of Omeros is US$579.50 million. Omeros has a price to earnings ratio (PE ratio) of -4.92.

OMER Últimas noticias

Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

Primary statistical analysis of overall survival compared TA-TMA patients treated with narsoplimab in its pivotal trial to a cohort of over 100 TA-TMA patients not treated with narsoplimab in an...

Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting

-- Clinical Trial and Clinical Pharmacology Data Support Upcoming Enrollment of Omeros’ Zaltenibart Phase 3 Clinical Program in PNH -- Omeros Corporation (Nasdaq: OMER) today announced that two...

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

-- Presentations Highlight Progress in Late-Stage Development of Lead MASP-3 Inhibitor Zaltenibart -- Omeros Corporation (Nasdaq: OMER) today announced that two abstracts directed to zaltenibart...

Omeros Corporation Provides Update on Progress Toward BLA Resubmission

Omeros Corporation (Nasdaq: OMER) today announced an update on its progress toward planned resubmission of its biologics license application (“BLA”) for narsoplimab, the company’s first-in-class...

Omeros Corporation Reports Third Quarter 2024 Financial Results

– Conference Call Today at 4:30 p.m. ET Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30...

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2024, on Wednesday, November 13, 2024, after the market...

FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy

-- Phase 3 Studies on the Horizon in both PNH and C3G -- Omeros Corporation today announced that zaltenibart (OMS906) has received rare pediatric disease designation from the U.S. Food and Drug...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.2793-2.7171110873310.279313.69.88240418010.2359773CS
4-1.94-16.247906197711.9413.67.211013239.97722337CS
125.97148.1389578164.0313.63.759573598.360188CS
266.14159.0673575133.8613.63.546120237.21561577CS
526.36174.7252747253.6413.62.765530795.67077077CS
1562.4131.75230566537.5913.60.926963244.46978368CS
260-5.22-34.29697766115.2225.490.927632608.49693184CS

OMER - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Omeros?
El precio actual de las acciones de Omeros es US$ 10.00
¿Cuántas acciones de Omeros están en circulación?
Omeros tiene 57,949,760 acciones en circulación
¿Cuál es la capitalización de mercado de Omeros?
La capitalización de mercado de Omeros es USD 579.5M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Omeros?
Omeros ha negociado en un rango de US$ 2.76 a US$ 13.60 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Omeros?
El ratio precio/beneficio de Omeros es -4.92
¿Cuál es la moneda de reporte de Omeros?
Omeros presenta sus resultados financieros en USD
¿Cuál es el último beneficio anual de Omeros?
El último beneficio anual de Omeros es USD -117.81M
¿Cuál es la dirección registrada de Omeros?
La dirección registrada de Omeros es 3400 CAPITOL BLVD SE, TUMWATER, WASHINGTON, 98501
¿Cuál es la dirección del sitio web de Omeros?
La dirección del sitio web de Omeros es www.omeros.com
¿En qué sector industrial opera Omeros?
Omeros opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
MGIHMillennium Group International Holdings Ltd
US$ 5.09
(232.68%)
8.29M
ADDColor Star Technology Company Ltd
US$ 4.56
(111.11%)
3.13M
WAFUWah Fu Education Group Ltd
US$ 2.56
(47.13%)
3.78M
TIRXTian Ruixiang Holdings Ltd
US$ 2.86
(41.58%)
554.2k
LICNLichen China Limited
US$ 0.2816
(34.03%)
13.55M
NEUPNeuphoria Therapeutics Inc
 4.04
(-39.06%)
30.33k
HOURHour Loop Inc
US$ 2.94
(-33.18%)
196.58k
AVGRAvinger Inc
US$ 1.04
(-28.28%)
344.73k
CREVCarbon Revolution Public Ltd
US$ 6.60
(-27.95%)
29.15k
SVRESaverOne 2014 Ltd
US$ 1.10
(-27.15%)
43.43k
LICNLichen China Limited
US$ 0.2816
(34.03%)
13.55M
MGIHMillennium Group International Holdings Ltd
US$ 5.09
(232.68%)
8.29M
WAFUWah Fu Education Group Ltd
US$ 2.56
(47.13%)
3.78M
LITMSnow Lake Resources Ltd
US$ 0.6503
(11.18%)
3.58M
LAESSEALSQ Corporation
US$ 5.53
(1.10%)
3.25M

OMER Discussion

Ver más
glenn1919 glenn1919 1 mes hace
omer................................nice miss.................................
👍️0
TrendTrade2016 TrendTrade2016 1 mes hace
OMER MONSTER PLAY OF THE DAY
👍️0
Monksdream Monksdream 1 año hace
OMER new 52=week low
Then bounce
👍️0
shurtha2000 shurtha2000 1 año hace
$341M cash and $12M recievables
👍️0
starkd748 starkd748 2 años hace
Gap filled 6s 7s next top
👍️0
Roadtojourney Roadtojourney 2 años hace
With the type of news this should have been above 5 not sure whats wrong here?
👍️0
starkd748 starkd748 2 años hace
3.20 gap must fill now
👍️0
TheFinalCD TheFinalCD 2 años hace
OMER $200M PAYMENT
👍️0
makinezmoney makinezmoney 2 años hace
$OMER: She back on fire now............ sheeeshhhhhhhhhhhhhh


Go baby goooooooooo.......... $3 breaker upside




GO $OMER
👍️0
starkd748 starkd748 2 años hace
Weeeeeeee
👍️0
starkd748 starkd748 2 años hace
We get some 5s I'm backing up the truck
👍️0
starkd748 starkd748 2 años hace
Was a good trade but it's been done since 7s
👍️0
starkd748 starkd748 2 años hace
Weeeeee
👍️0
starkd748 starkd748 2 años hace
Weeeeeeeeeeeee
👍️0
starkd748 starkd748 2 años hace
Yesss
👍️0
starkd748 starkd748 2 años hace
Looking good
👍️0
starkd748 starkd748 2 años hace
Weeeeee
👍️0
starkd748 starkd748 2 años hace
Yesss
👍️0
starkd748 starkd748 2 años hace
Bounced off the low 3s time to load
👍️0
starkd748 starkd748 2 años hace
Maybe an A B C ... 2.17 might coming
👍️0
starkd748 starkd748 2 años hace
Not ready yet
👍️0
starkd748 starkd748 2 años hace
I like this at a certain fib level hehehe
👍️0
bandit007 bandit007 2 años hace
Great day here! $OMER
👍️0
bandit007 bandit007 3 años hace
Breaking out!
👍️0
bandit007 bandit007 3 años hace
Looking good here. Steady climb
👍️0
bandit007 bandit007 3 años hace
Looking good here. Steady climb
👍️0
Scott 75 Scott 75 3 años hace
Wow! Thanks for sharing. I can't believe with all that going for it and the price is so beaten down.
👍️0
Nefyn Nefyn 3 años hace
So what happens to OMER…a public company with tons of cash and no business operations?
👍️0
JackAskSlap JackAskSlap 3 años hace
Bahhh Bahhh

gonna do this all day long
👍️0
JackAskSlap JackAskSlap 3 años hace
another round for the apes Lets GO !!
👍️0
JackAskSlap JackAskSlap 3 años hace
Glad I'm just a robot no emotions needed
👍️0
JackAskSlap JackAskSlap 3 años hace
Fk with BB My new addiction
👍️0
JackAskSlap JackAskSlap 3 años hace
IN now I'm gonna tick flip this POS to death
👍️0
JackAskSlap JackAskSlap 3 años hace
Trying for the baseline
no holds barred..
👍️0
Jess070283 Jess070283 3 años hace
Load it up!$$$
👍️0
TheGreenReaper TheGreenReaper 3 años hace
OMER$$$$
👍️0
Golden Cross Golden Cross 3 años hace
$14 Targeting
👍️0
crudeoil24 crudeoil24 3 años hace
59M trading float. Huge news out >
👍️0
crudeoil24 crudeoil24 3 años hace
Shorts feeling the heat!!!!! >
👍️0
crudeoil24 crudeoil24 3 años hace
>>>>> GANGBUSTERS <<<<< $$$$$

OMER
👍️0
crudeoil24 crudeoil24 3 años hace
OMER > That is a sweet revenue deal. OMER heading to $20.00+
$125 million upfront payment and $200 million on achievement of commercial milestone
Royalties of 50% on U.S. net sales until the earlier of either January 1, 2025 or payment of the $200-million milestone, after which royalties adjust to 30% of U.S. net sales
Royalties of 15% on ex-U.S. net sales
OMIDRIA to become a premier product in Rayner’s ophthalmology franchise
In addition to acquiring the OMIDRIA commercial organization, including the current OMIDRIA sales force, Rayner plans to further expand its U.S. and ex-U.S. sales forces
👍️0
TheFinalCD TheFinalCD 3 años hace
https://ih.advfn.com/stock-market/NASDAQ/omeros-OMER/stock-news/86711139/omeros-announces-agreement-to-sell-omidria-franch
👍️0
Frankestin Frankestin 3 años hace
Here are the 5!
Very interesting if it goes under!
I would be tempted to open the position now!
👍️0
Frankestin Frankestin 3 años hace
Someone says 5 ... will it get there?
I would like to enter but of course they spend a lot on research and development... and for sell
👍️0
Frankestin Frankestin 3 años hace
ooOOoo
I take a handful these days!
👍️0
Termite7 Termite7 3 años hace
Buying opportunity???
👍️0
frugalNorwegian frugalNorwegian 4 años hace
I created a page on my site talking about OMER. Let me know if I am missing any nuggets. Thanks.

https://frugalnorwegian.com/omer

Summary: This company is a prime candidate for a buyout if FDA approval is given.
👍️0
Dr_Thorfin Dr_Thorfin 4 años hace
If one is worried about fda's delay, Check out @alanrobertross message on StockTwits http://stocktwits.com/alanrobertross/message/333077805
👍️0
umiak umiak 4 años hace
Tute ownership up to 78% been hovering around 50% for years. 20% short
👍️0
umiak umiak 4 años hace
Not new news but I like the smart reporting style:
Omeros's Biologics License Application for Blood Vessel Damage Treatment Candidate Accepted for Priority Review by FDA

1/19/21, 8:06 AM
10:06 AM EST, 01/19/2021 (MT Newswires) -- Omeros (OMER) said Tuesday its biologics license application for narsoplimab, a potential treatment for transplant-associated thrombotic microangiopathy, has been accepted for priority review by the US Food and Drug Administration.

Thrombotic microangiopathy is characterized by a pattern of damage in the small blood vessels.

The FDA has set the Prescription Drug User Fee Act action date on July 17.
👍️0

Su Consulta Reciente

Delayed Upgrade Clock